Rydén C, Yacoub A I, Maxe I, Heinegård D, Oldberg A, Franzén A, Ljungh A, Rubin K
Department of Medical and Physiological Chemistry, University of Uppsala, Sweden.
Eur J Biochem. 1989 Sep 15;184(2):331-6. doi: 10.1111/j.1432-1033.1989.tb15023.x.
Bone sialoprotein is selectively bound by Staphylococcus aureus cells isolated from patients suffering from infections of bone tissue [Rydén, C., Maxe, I., Franzén, A., Ljungh, A., Heinegård, D. & Rubin, K. (1987) Lancet II, 514]. In the present communication the binding of bone sialoprotein to staphylococcal cells is characterized in more detail. 125I-Labelled bone sialoprotein bound to suspended staphylococcal cells in a time-dependent, saturable and reversible manner. Binding was inhibited by unlabelled bone sialoprotein and by an amino-terminal CNBr fragment of bone sialoprotein that did not contain the eukaryotic cell-binding site. Binding was furthermore inhibited by lysates obtained from Escherichia coli lysogens carrying a lambda gt11 phage-encoding bone sialoprotein. In contrast, binding was not inhibited by a bacterial lysate from an osteopontin lambda gt11 lysogen, nor by N-linked oligosaccharide isolated from bone sialoprotein or by proteoglycan from rat chondrosarcoma containing clustered O-linked oligosaccharides of the same structure as those of bone sialoprotein. These results indicate that the major staphylococcal-binding site resides in the bone sialoprotein core protein and not in the carbohydrate side chains. No inhibition of bone sialoprotein binding could be detected for whole human serum or purified plasma proteins such as fibronectin, fibrinogen and IgG. Likewise, staphylococcal protein A or rat collagen type I did not inhibit the binding of bone sialoprotein. The latter results indicate that the binding site for bone sialoprotein on staphylococcal cells was not any of the hitherto described staphylococcal cell-surface proteins. Binding data indicated an average of 1000 bone-sialoprotein-binding sites/bacterial cell.
骨唾液蛋白可被从患有骨组织感染的患者体内分离出的金黄色葡萄球菌细胞选择性结合[Rydén, C., Maxe, I., Franzén, A., Ljungh, A., Heinegård, D. & Rubin, K. (1987) Lancet II, 514]。在本报告中,对骨唾液蛋白与葡萄球菌细胞的结合进行了更详细的表征。125I标记的骨唾液蛋白以时间依赖性、可饱和且可逆的方式与悬浮的葡萄球菌细胞结合。未标记的骨唾液蛋白以及不含真核细胞结合位点的骨唾液蛋白氨基末端CNBr片段可抑制结合。此外,携带编码骨唾液蛋白的λgt11噬菌体的大肠杆菌溶原菌产生的裂解物也可抑制结合。相比之下,骨桥蛋白λgt11溶原菌的细菌裂解物、从骨唾液蛋白中分离出的N-连接寡糖或来自大鼠软骨肉瘤且含有与骨唾液蛋白结构相同的成簇O-连接寡糖的蛋白聚糖均不能抑制结合。这些结果表明,主要的葡萄球菌结合位点位于骨唾液蛋白核心蛋白中,而非碳水化合物侧链中。对于全人血清或纯化的血浆蛋白(如纤连蛋白、纤维蛋白原和IgG),未检测到对骨唾液蛋白结合的抑制作用。同样,葡萄球菌蛋白A或大鼠I型胶原也不能抑制骨唾液蛋白的结合。后一结果表明,葡萄球菌细胞上骨唾液蛋白的结合位点不是迄今所描述的任何一种葡萄球菌细胞表面蛋白。结合数据表明,平均每个细菌细胞有1000个骨唾液蛋白结合位点。